Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide

In patients with metastatic castrate‐resistant prostate cancer (mCRPC), circulating tumor DNA (ctDNA) analysis offers novel opportunities for the development of non‐invasive biomarkers informative of treatment response with novel agents targeting the androgen‐receptor (AR) pathway, such as abiratero...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Int J Cancer
Huvudupphovsmän: Belic, Jelena, Graf, Ricarda, Bauernhofer, Thomas, Cherkas, Yauheniya, Ulz, Peter, Waldispuehl‐Geigl, Julie, Perakis, Samantha, Gormley, Michael, Patel, Jaymala, Li, Weimin, Geigl, Jochen B., Smirnov, Denis, Heitzer, Ellen, Gross, Mitchell, Speicher, Michael R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2018
Ämnen:
Tumor Markers and Signatures
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6099279/
https://ncbi.nlm.nih.gov/pubmed/29574703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31397
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk